Download Product Insert (PDF)
PRODUCT INFORMATION Doxofylline Item No. 18746
CAS Registry No.: 69975-86-6
Formal Name: 7-(1, 3- dioxolan- 2- ylmethyl) - 3, 7- dihydro- O N 1,3- dimethyl-1H- purine-2,6- dione N MF: C11H14N4O4 N
FW: 266.3 N Purity: ≥98% O O Stability: ≥2 years at -20°C Supplied as: A crystalline solid O UV/Vis.: λmax: 273 nm
Laboratory Procedures
For long term storage, we suggest that doxofylline be stored as supplied at -20°C. It should be stable for at least two years. Doxofylline is supplied as a crystalline solid. A stock solution may be made by dissolving the doxofylline in the solvent of choice. Doxofylline is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of doxofylline in ethanol is approximately 0.5 mg/ml and approximately 20 mg/ml in DMSO and DMF. Doxofylline is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, doxofylline should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Doxofylline has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Description
Doxofylline is a methylxanthine bronchodilator that has been examined in clinical trials involving patients with either bronchial asthma or chronic obstructive pulmonary disease.1 Its mechanism of action is related to its ability to inhibit phosphodiesterase activity and, thus, increase cAMP.2 Compared to other xanthine derivatives, which have direct arrhythmogenic effects, doxofylline demonstrates decreased affinity towards adenosine A1 and A2 receptors, does not interfere with calcium influx into cells, and does not antagonize the action of calcium-channel blockers.2,3
References
1. Akram, M.F., Nasiruddin, M., Ahmad, Z., et al. Doxofylline and theophylline: A comparative clinical study. J. Clin. Diagn. Res. 6(10), 1681-1684 (2012). 2. Shukla, D., Chakraborty, S., Singh, S., et al. Doxofylline: A promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin. Pharmacother. 10(14), 2343-2356 (2009). 3. Dini, F.L. and Cogo, R. Doxofylline: A new generation xanthine bronchodilator devoid of major cardiovascular adverse effects. Curr. Med. Res. Opin. 16(4), 258-268 (2001).
WARNING CAYMAN CHEMICAL THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE. 1180 EAST ELLSWORTH RD SAFETY DATA ANN ARBOR, MI 48108 · USA This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution. PHONE: [800] 364-9897
WARRANTY AND LIMITATION OF REMEDY [734] 971-3335 Buyer agrees to purchase the material subject to Cayman’s Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website. FAX: [734] 971-3640 [email protected] Copyright Cayman Chemical Company, 01/14/2016 WWW.CAYMANCHEM.COM